Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Hindustan Copper hits new high, Tata Capital settles SEBI case, Ola Electric and Ajanta Pharma in focus amid a flat market ...

Mumbai-based Ajanta Pharma has entered into an agreement with Biocon to commercialise its version of semaglutide across ...

Under the agreement, Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries Shares of Ajanta ...

Semalutide improves glycaemic control in adults. The product patent expires in most these markets in March 2026. Ajanta ...

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

Biotech firm Biocon on Tuesday said it has signed an out-licensing agreement with Ajanta Pharma to market its diabetes drug ...

Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, West Asia, and Central Asia ...

Ajanta Pharma partners with Biocon to market Semaglutide in 26 countries, aiming for commercialization after 2026 regulatory approvals.